Gen-Probe Inc. (NSDQ:GPRO) bought Waukesha, Wis.-based GTI Diagnostics in a self-funded $53 million cash deal.
The acquisition allows the San Diego-based company to expand its transplant diagnostics business, according to Gen-Probe.
GTI develops medical diagnostic assays for the transplantation, blood bank and specialty coagulation markets. Its human leukocyte antigen, or HLA, antibody detection products are already sold by Gen-Probe under the Lifecodes brand, but the company has also commercialized a number of other HLA-related testing products, including serological typing trays, enzyme immunoassays and molecular typing products for donor-recipient matching, according to Gen-Probe.
GTI was owned by Cleveland-based private equity firm the Riverside Co. and investors, including the company’s founders.
Esperion Sets Its Sights on New Areas While Maintaining Commitment to Cardiovascular Health
In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases
The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.